Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population

Overview

This study is divided into two parts: Part 1: An interventional study, with a pre-post study design to determinate the grade of knowledge of established GC risk factors. Part 2: An observational study to know impact on prevalence and infection eradication of H. pylori

Full Title of Study: “Interventional Study at the Primary and Secondary Levels of Prevention for Knowledge Regarding GC Risk Factors in EU and CELAC Populations”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2021

Detailed Description

Part 1: to determinate the grade of knowledge of established GC risk factors and identification of attitudes about, GC screening programs at baseline, prior to the intervention though an educational program. Part 2: to generate an H. pylori registry, to know its impact on prevalence and infection eradication rate at 6th, 12th, 24th and at Month 36th.

Clinical Trial Outcome Measures

Primary Measures

  • knowledge GC risk factors and symptoms
    • Time Frame: 3 years
    • Compare the results obtained through a knowledge of CG risk factors by study-specific questionnaire before and after an educational intervention
  • H. pylori prevalence and drug resistance
    • Time Frame: 3 years
    • Generate an H. pylori registry, to know its impact on prevalence and infection eradication rate at months 6th, 12th, 24th and 36th.

Participating in This Clinical Trial

Part A: Educational Intervention Inclusion criteria

  • Subjects >18 years old, from EU and CELAC countries participating in this study. – Has given and signed the IC to participate in this study. Exclusion criteria – Subjects who have received some prior preparation (Cancer Gastric Information). – Subjects who have previous Knowledge in Gastric Cancer (Example, near relatives who have suffered Gastric Cancer Part B: H. pylori Register Inclusion criteria – Subjects ≥18 years old diagnose from H. pylori infection and treated at participant sites – Has given and signed the IC. Exclusion criteria – Subjects with chronic gastritis without confirmed diagnose of H. pylori infection, pathologically of by urease test. – Patient's with CG diagnosis (including gastroesophageal junction cancer).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Investigator Details

  • Lead Sponsor
    • Fundación para la Investigación del Hospital Clínico de Valencia
  • Collaborator
    • Instituto Nacional de Cancerologia de Mexico
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Andrés Cervantes, MD, 0034961973543, andres.cervantes@uv.es

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.